| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Radiopharmacology, Department of Radiology [V. V. R., D. P-W.], and Department of Pathology [D. C. A.], Harvard Medical School, Brigham and Women's Hospital and Children's Hospital, Boston, Massachusetts 02115
Overexpression of P-glycoprotein, the plasma membrane protein product of the MDR1 gene, is a major determinant in the development of resistance to a large number of cancer chemotherapeutic agents. A battery of antibodies, including the MDR1 gene-specific monoclonal antibody (mAb) C494, is used to evaluate human tissues in clinical multidrug resistance surveillance and modulation trials. In rat liver fractions, we report that mAb C494 strongly cross-reacted with a nonmembranous Mr
130,000 protein, comigrating with core-glycosylated human MDR1 on 7% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. By immunoblotting and microsequence analysis, this protein was identified as pyruvate carboxylase (PC), an abundant mitochondrial enzyme. A search of the National Center for Biotechnology Information data base, using the epitope-specific sequence of mAb C494, revealed that PC (mouse) contains four of the five most reactive amino acids (TLEG), located near the COOH-terminal end of PC at positions 11671170. mAb C494 specifically reacted with PC purified from bovine liver; immunoreactivity was completely abolished by preincubating mAb C494 in the presence of excess synthetic C494 epitope-specific peptide. Furthermore, in cryosections of human skeletal muscle, a tissue known not to express P-glycoprotein, peptide-displaceable immunohistochemical staining with mAb C494 showed a distinct mitochondrial pattern specific to type 1 fibers. Variable immunostaining results were obtained with formaldehyde-fixed, paraffinembedded muscle and isolated liver mitochondrial preparations. In summary, mAb C494 cross-reacted strongly with rat, bovine, and human PC. Caution is warranted in interpretation of immunoblots and immunohistochemical sections with this putative MDR1 gene-specific mAb.
1 This work was supported in part by a grant from the Milton Fund, Harvard Medical School, and by NIH Grant CA 09536.
2 To whom requests for reprints should be addressed, at Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.
3 D. P-W. is an Established Investigator of the American Heart Association.
Received 7/20/93. Accepted 1/17/94.
This article has been cited by other articles:
![]() |
S. M. Sisodiya, W.-R. Lin, B. N. Harding, M. V. Squier, and M. Thom Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy Brain, January 1, 2002; 125(1): 22 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Wunder, S. B. Bull, V. Aneliunas, P. D. Lee, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, M. J. Rock, et al. MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study J. Clin. Oncol., July 14, 2000; 18(14): 2685 - 2694. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |